Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (17720)	3/19/1998 1:55:00 PM
From: Wallace Rivers	Read Replies (2) \| Respond to of 32384

Bernie; The earnings are from a recollection I had from the last earnings release, and I could be incorrect...if I am, I apologize, not meaning to put forth FUD. Here is a tiny synopsis of what happened atRJA conference: RJA has a new biotech analyst who will presumably initiate coverage on this company (my guess is sometime in April or May). The feeling my contact received is that people at that presentation felt that LGND has one of the best pipelines in the biz. In my scribbled notes (and perhaps this may answer the question re my statement), it was stated that LGND probably will achieve profitability next year. One source at the conference felt that the osteoporosis drug has, down the road, the potential to be the biggest drug in its pipeline. More to come - please understand I am not a biotech icon, rather a humble investor, with some dead brain cells! Best, Wallace